Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : DYAX: Dyax Corp. -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (17)	6/20/2001 10:40:15 AM
From: keokalani'nui	Read Replies (2) \| Respond to of 197

SOURCE: Cambridge Antibody Technology Cambridge Antibody Technology Announces Grant of 'Winter II' Patent in US MELBOURN, England, June 20 /PRNewswire/ -- Cambridge Antibody Technology (LSE: CAT; Nasdaq: CATG) today announced the issue of a US patent covering antibody expression libraries, the ``Winter II'' patent, US 6,248,516. The US Winter II patent is entitled ``Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors,'' and was issued on 19 June 2001. It is generally directed to antibody variable domain expression libraries carrying a diversity of CDR3 sequences and methods of making such libraries. The patent is co-owned by the Medical Research Council, The Scripps Research Institute and Stratagene. CAT is the sole exploiter of the intellectual property rights arising under the patent, subject to certain rights reserved by the co-owners and their pre-existing licensees. CAT also announced the filing of an infringement suit alleging that MorphoSys AG and MorphoSys USA, Inc., infringe the Winter II patent. The suit was filed in the United States District Court for the Southern District of California, in San Diego. CAT has previously sued MorphoSys in Germany for infringement of the European counterpart to the Winter II patent.